⌘K
Loading ticker…
As of 2026-08-24, Candel Therapeutics, Inc. Common Stock (CADL) has a 3-month relative strength percentile of 96 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 83. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.2%, relative volume 0.72×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
CADL is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 26.5% / 83.2%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
CADL is held by 14 ETFs as of May 2026. Top owner: VTWO at 0.01% weight, $2M notional. Top 3 carry $3M.
Held by 23 ETFs · $24M across latest filings · largest weight 0.39% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $25K |
| — |
| BIB | 0.03% | $22K | +0.02 pp |
| MSSM | 0.00% | $19K | — |
| ITWO | 0.01% | $18K | — |
| URTY | 0.00% | $14K | — |
Showing 10 of 14 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CADL Jan avg: 4.20% median: -4.10% win: 50% σ: 27.78% n: 4 2022-04-12 → 2026-07-31 | CADL Feb avg: 7.49% median: 8.42% win: 50% σ: 33.45% n: 4 2022-04-12 → 2026-07-31 | CADL Mar avg: -20.94% median: -20.03% win: 0% σ: 13.09% n: 4 2022-04-12 → 2026-07-31 | CADL Apr avg: 64.94% median: -4.44% win: 40% σ: 158.55% n: 5 2022-04-12 → 2026-07-31 | CADL May avg: 18.78% median: 17.05% win: 100% σ: 11.64% n: 5 2022-04-12 → 2026-07-31 | CADL Jun avg: -8.80% median: -14.06% win: 20% σ: 20.23% n: 5 2022-04-12 → 2026-07-31 | CADL Jul avg: 0.32% median: -4.32% win: 20% σ: 15.80% n: 5 2022-04-12 → 2026-07-31 | CADL Aug avg: 7.14% median: 12.45% win: 75% σ: 11.56% n: 4 2022-04-12 → 2026-07-31 (current) | CADL Sep avg: -10.84% median: -10.71% win: 25% σ: 11.17% n: 4 2022-04-12 → 2026-07-31 | CADL Oct avg: -14.68% median: -13.00% win: 25% σ: 20.00% n: 4 2022-04-12 → 2026-07-31 | CADL Nov avg: -8.03% median: -10.34% win: 0% σ: 5.33% n: 4 2022-04-12 → 2026-07-31 | CADL Dec avg: 42.18% median: 40.98% win: 100% σ: 38.30% n: 4 2022-04-12 → 2026-07-31 |